Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | PPME1 | Q9Y570 | 8/20 | 0.38 |
| ▸ | APEH | P13798 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 3/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15358101 | 0.81 | RAPGEF4 (0.36) | PPME1APEHALDH1A1HTTLMNA | |
| SCHEMBL29713729 | 0.76 | PPME1 (0.55) | HTR6PPME1APEHALDH1A1HTT | |
| SCHEMBL29512049 | 0.72 | HTR6 (0.38) | HTR6PPME1APEHRAPGEF4 | |
| SCHEMBL15155241 | 0.70 | HTR6 (0.39) | HTR6PPME1APEHALDH1A1RAPGEF4 | |
| SCHEMBL5776603 | 0.68 | HTR6 (0.38) | HTR6PPME1APEHHTTRAPGEF4 | |
| SCHEMBL28295721 | 0.65 | ALDH1A1 (0.33) | HTR6PPME1APEHALDH1A1LMNA | |
| SCHEMBL8634800 | 0.65 | PCSK9 (0.44) | HTR6ALDH1A1 | |
| SCHEMBL2460281 | 0.65 | TRIM24 (0.52) | HTR6PPME1APEHALDH1A1 | |
| SCHEMBL23798598 | 0.64 | MAOA (0.35) | ALDH1A1LMNAGLAPGRAR | |
| SCHEMBL65584 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9567304-B2 | Quinazolinedione derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-02-14 | — | — | US | disclosed |
| US-9567304-B2 | Quinazolinedione derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-02-14 | — | — | US | disclosed |
| US-9567304-B2 | Quinazolinedione derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2017-02-14 | — | — | US | disclosed |
| EP-2842946-B1 | QUINAZOLINEDIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| EP-2842946-B1 | QUINAZOLINEDIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-20150141400-A1 | QUINAZOLINEDIONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-05-21 | — | — | US | disclosed |
| US-20150141400-A1 | QUINAZOLINEDIONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-05-21 | — | — | US | disclosed |
| US-20150141400-A1 | QUINAZOLINEDIONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2842946-A1 | QUINAZOLINEDIONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-03-04 | — | — | EP | disclosed |
| EP-2842946-A1 | QUINAZOLINEDIONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-03-04 | — | — | EP | disclosed |
| CN-104379568-A | Quinazolinedione derivative | CHUGAI PHARMACEUTICAL CO LTD | 2015-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141400-A1 | QUINAZOLINEDIONE DERIVATIVE | PPARD, SLC5A2, PPARG | HTR6 946/4885PPME1 3469/4885APEH 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.